Get the Stockscreener App
3.64
0.82%
-0.03
Genfit Adr stock is traded at $3.64, with a volume of 3,067.
It is down -0.82% in the last 24 hours and up +6.74% over the past month.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
See More
Previous Close:
$3.67
Open:
$3.86
24h Volume:
3,067
Relative Volume:
0.24
Market Cap:
$178.17M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-4.9585
EPS:
-0.7341
Net Cash Flow:
-
1W Performance:
+3.70%
1M Performance:
+6.74%
6M Performance:
-33.82%
1Y Performance:
+5.51%
1-Day Range:
$3.64
$3.86
1-Week Range:
$3.28
$3.86
52-Week Range:
$2.55
$6.4229
Genfit Adr Stock (GNFT) Company Profile
Compare GNFT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
3.64 | 178.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-23-20 | Upgrade | Stifel | Hold → Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Underperform |
| May-13-20 | Downgrade | Kepler | Buy → Reduce |
| May-12-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-12-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-29-19 | Reiterated | B. Riley FBR | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Apr-24-19 | Initiated | SVB Leerink | Outperform |
| Apr-22-19 | Initiated | Barclays | Overweight |
View All
Genfit Adr Stock (GNFT) Latest News
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
GENFIT annonce les résultats préliminaires de l’Offre de Rachat proposée aux porteurs d’OCEANEs 2025 et la Convocation de l’assemblée générale des porteurs d’OCEANEs 2025 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading - TradingView
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
GENFIT: Ipsen and GENFIT enter into exclusive licensing - GlobeNewswire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Genfit Adr Stock (GNFT) Financials Data
There is no financial data for Genfit Adr (GNFT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):